ERR2278856
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.410
- MYOGENESIS+0.340
- ALLOGRAFT_REJECTION+0.320
- BILE_ACID_METABOLISM+0.280
- INTERFERON_ALPHA_RESPONSE+0.250
- FATTY_ACID_METABOLISM+0.230
- INTERFERON_GAMMA_RESPONSE+0.200
- KRAS_SIGNALING_DN+0.190
- KRAS_SIGNALING_UP+0.170
- PEROXISOME+0.160
Top 10 suppressed
- MYC_TARGETS_V2-0.480
- E2F_TARGETS-0.400
- WNT_BETA_CATENIN_SIGNALING-0.400
- G2M_CHECKPOINT-0.390
- NOTCH_SIGNALING-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- MITOTIC_SPINDLE-0.360
- TGF_BETA_SIGNALING-0.360
- CHOLESTEROL_HOMEOSTASIS-0.350
- APICAL_JUNCTION-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25043623 | — | — | 0.848 |
| 2 | ERR2598274 | fetal | fetal | 0.845 |
| 3 | ERR2598272 | fetal | fetal | 0.832 |
| 4 | ERR2598331 | fetal | fetal | 0.817 |
| 5 | ERR2598273 | fetal | fetal | 0.798 |
| 6 | ERR2598330 | fetal | fetal | 0.790 |
| 7 | BS_7BTZQKYY | EPN | EPN Tumor | 0.787 |
| 8 | C3N-00223 | — | cohortA1 | 0.781 |
| 9 | ERR2598271 | fetal | fetal | 0.781 |
| 10 | SRR660638 | GTEX | — | 0.774 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.250 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| PEROXISOME | 0.160 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.140 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.090 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.050 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.040 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.030 | Inavolisib | — uncovered |
| COMPLEMENT | 0.010 | Inavolisib | — uncovered |